These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 15593037)

  • 1. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study.
    Hsu PY; Lin CL; Yu CC; Chien CC; Hsiau TG; Sun TH; Huang LM; Yang CW
    J Nephrol; 2004; 17(5):693-700. PubMed ID: 15593037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dialysis purity on uremic dyslipidemia.
    Schiffl H; Lang SM
    Ther Apher Dial; 2010 Feb; 14(1):5-11. PubMed ID: 20438514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients.
    Matsuhashi N; Yoshioka T
    Nephron; 2002; 92(3):601-4. PubMed ID: 12372943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A single centre study about the effects of HFR on anemia].
    Righetti M; Ferrario GM; Milani S; Serbelloni P; Sessa A
    G Ital Nefrol; 2004; 21 Suppl 30():S168-71. PubMed ID: 15750978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
    Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
    J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M; Duncan HJ; Kant KS
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis.
    Arizono K; Nomura K; Motoyama T; Matsushita Y; Matsuoka K; Miyazu R; Takeshita H; Fukui H
    Blood Purif; 2004; 22 Suppl 2():26-9. PubMed ID: 15655319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reticulocyte hemoglobin content in hemodialysis patients with acute infection.
    Mitsuiki K; Harada A; Miyata Y
    Clin Exp Nephrol; 2004 Sep; 8(3):257-62. PubMed ID: 15480904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of inflow of endotoxin and its fragments in patients on maintenance hemodialysis.
    Suzuki H; Honda H; Kato N; Michihata T; Takahashi K; Shishido K; Akizawa T
    Blood Purif; 2011; 31(4):268-75. PubMed ID: 21242680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients.
    Furuya R; Kumagai H; Takahashi M; Sano K; Hishida A
    Blood Purif; 2005; 23(4):311-6. PubMed ID: 15980621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the quality of water used for dialysis on the efficacy of hemodialysis: a single-center experience from Morocco.
    Akhmouch I; Asserraji M; Bahadi A; Bouaiti E; Alayoude M; Aatif T; Hamzi MA; Kawtar H; Allam M; Oualim Z
    Saudi J Kidney Dis Transpl; 2011 May; 22(3):576-80. PubMed ID: 21566327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of iron deficiency in erythropoietin sensitivity in dialysis patients with elevated C-reactive protein].
    Martone M; Zanchi R; Panzetta G
    G Ital Nefrol; 2003; 20(1):31-7. PubMed ID: 12647284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
    Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
    Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements--a randomized study.
    Lamas JM; Alonso M; Sastre F; García-Trío G; Saavedra J; Palomares L
    Nephrol Dial Transplant; 2006 Oct; 21(10):2851-8. PubMed ID: 16822792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.